Ake­bia forges $1B US pact with Ot­su­ka on lead drug for CKD, shares spike

Ake­bia $AK­BA has struck a land­mark $1 bil­lion part­ner­ship with Ot­su­ka for its late-stage drug vadadu­s­tat, an oral treat­ment for ane­mia re­lat­ed to chron­ic kid­ney dis­ease. The deal comes with $265 mil­lion in com­mit­ted cash, in­clud­ing $125 mil­lion as an up­front pay­ment with an­oth­er $35 mil­lion due in ear­ly 2017.

Ot­su­ka gains co-com­mer­cial­iza­tion rights in the US for Ake­bia’s drug, hand­ing over $105 mil­lion to help cov­er de­vel­op­ment costs and of­fer­ing mile­stones reach­ing up to $765 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER